Regulatory Developments October 2019

03a_RegNews_Alternate_770x2953.jpg


FDA announces the rates for prescription drug and biosimilar user fees for fiscal year 2020, a draft guidance for industry, Neonatal Studies for Drugs and Biological Products, and more.

 

Related Stories

Table of Contents
Regulatory Developments
October/November 2019